Phathom Pharmaceuticals, Inc. (PHAT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
This page provides the complete earnings calendar, dividend schedule, and financial data for Phathom Pharmaceuticals, Inc. in 2026. The next earnings report is expected on November 5, 2026.
Phathom Pharmaceuticals beat consensus estimates in its latest earnings report, with EPS of $0 compared with an expected -$0.1894 and revenue of $74.27 million exceeding estimates by 2.2%. In the prior quarter, EPS missed expectations while revenue came in ahead of estimates.
Dividend calendar
No dividend history available.
EPS (Earnings Per Share)
Revenue
Company profile
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
